.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Julphar
Express Scripts
Colorcon
Boehringer Ingelheim
Deloitte
Johnson and Johnson
Covington
Chinese Patent Office
Cantor Fitzgerald

Generated: January 17, 2018

DrugPatentWatch Database Preview

US Patents With Foreign Priority to Germany Patent: 199 62 924

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Janssen PharmsXARELTOrivaroxabanTABLET;ORAL022406-001Jul 1, 2011RXYesNo➤ Subscribe➤ SubscribeY
Janssen PharmsXARELTOrivaroxabanTABLET;ORAL022406-002Nov 4, 2011RXYesNo➤ Subscribe➤ SubscribeY
Janssen PharmsXARELTOrivaroxabanTABLET;ORAL022406-003Nov 4, 2011RXYesYes➤ Subscribe➤ SubscribeY
Janssen PharmsXARELTOrivaroxabanTABLET;ORAL022406-001Jul 1, 2011RXYesNo➤ Subscribe➤ SubscribeYYTREATMENT OF DEEP VEIN THROMBOSIS (DVT)
Janssen PharmsXARELTOrivaroxabanTABLET;ORAL022406-001Jul 1, 2011RXYesNo➤ Subscribe➤ SubscribeYYTREATMENT OF PULMONARY EMBOLISM (PE)
Janssen PharmsXARELTOrivaroxabanTABLET;ORAL022406-002Nov 4, 2011RXYesNo➤ Subscribe➤ SubscribeYYTREATMENT OF DEEP VEIN THROMBOSIS (DVT)
Janssen PharmsXARELTOrivaroxabanTABLET;ORAL022406-002Nov 4, 2011RXYesNo➤ Subscribe➤ SubscribeYYTREATMENT OF PULMONARY EMBOLISM (PE)
Janssen PharmsXARELTOrivaroxabanTABLET;ORAL022406-003Nov 4, 2011RXYesYes➤ Subscribe➤ SubscribeYYTREATMENT OF DEEP VEIN THROMBOSIS (DVT)
Janssen PharmsXARELTOrivaroxabanTABLET;ORAL022406-003Nov 4, 2011RXYesYes➤ Subscribe➤ SubscribeYYTREATMENT OF PULMONARY EMBOLISM (PE)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Table 'thinkbio_newdpw.patent_gazette' doesn't exist